Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

86
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
86
Drug-Receptor Interactions01:29

Drug-Receptor Interactions

8.4K
Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
8.4K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

69
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
69
Quantitative Aspects of Drug-Receptor Interaction01:30

Quantitative Aspects of Drug-Receptor Interaction

2.2K
The receptor occupancy theory connects a drug's response to the number of occupied receptors. With higher drug concentrations, more receptors are occupied, leading to increased responses. The formation of drug-receptor complexes involves association and dissociation rates, which reach equilibrium when the forward and backward reactions are equal. The equilibrium association constant (Ka) and its inverse, the equilibrium dissociation constant (Kd), indicate drug affinity. Higher Ka and lower...
2.2K
Therapeutic Drug Monitoring: Overview and Classification01:16

Therapeutic Drug Monitoring: Overview and Classification

531
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
531
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

72
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
72

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development and evaluation of multi-strategy fusion machine learning models for predicting postoperative recurrence in non-small cell lung cancer.

BMC medical imaging·2026
Same author

Interpretable chronic obstructive pulmonary disease identification using chest X-ray radiomics: a multicenter study.

Insights into imaging·2026
Same author

Discrepancy Between Preoperative CT and Pathological Tumor Diameters in Stage I Lung Adenocarcinoma and Its Association with Postoperative Recurrence.

Academic radiology·2026
Same author

Dual-branch spatio-temporal graph network for bearing fault diagnosis.

Scientific reports·2026
Same author

Longitudinal Associations Between Campus Exclusion, Experiential Avoidance and Depression Among Chinese Adolescents: Disentangling Between- and Within‑Person Effects.

Journal of adolescence·2026
Same author

The global clinical trial landscape for glaucoma over the past three decades: current status and future prospects.

Eye (London, England)·2026

Related Experiment Video

Updated: Apr 7, 2026

Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

19.8K

MFDR-DTI: Multisource Feature Decoupling and Dual-Level Reorganization Fusion for Accurate Drug-Target Interaction

Dan Xie1, Xue Yu1, Yuni Zeng2

  • 1College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou 310018, China.

ACS Omega
|April 6, 2026
PubMed
Summary

This study introduces MFDR-DTI, a novel deep learning framework for predicting drug-target interactions (DTIs). By decoupling and integrating diverse biochemical features, it significantly enhances DTI prediction accuracy and stability.

More Related Videos

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

4.7K
Mapping Dysfunctional Protein-Protein Interactions in Disease
09:39

Mapping Dysfunctional Protein-Protein Interactions in Disease

Published on: October 24, 2025

1.1K

Related Experiment Videos

Last Updated: Apr 7, 2026

Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

19.8K
A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

4.7K
Mapping Dysfunctional Protein-Protein Interactions in Disease
09:39

Mapping Dysfunctional Protein-Protein Interactions in Disease

Published on: October 24, 2025

1.1K

Area of Science:

  • Bioinformatics
  • Computational Chemistry
  • Drug Discovery

Background:

  • Accurate drug-target interaction (DTI) prediction is vital for efficient drug discovery.
  • Current deep learning methods struggle to integrate heterogeneous biochemical features from multiple sources.
  • Challenges include handling multilevel representations and feature imbalances during model training.

Purpose of the Study:

  • To propose MFDR-DTI, a novel framework for DTI prediction.
  • To effectively integrate diverse biochemical features using a unique decoupling and fusion mechanism.
  • To enhance model training stability and convergence efficiency through adaptive optimization.

Main Methods:

  • Developed MFDR-DTI framework utilizing Multisource Feature Decoupling Representation and Dual-level dynamic Reorganization Fusion.
  • Decoupled features into topological structure, physicochemical properties, and contextual semantics.
  • Implemented adaptive collaborative optimization strategy based on gradient statistics to manage feature branch contributions.

Main Results:

  • MFDR-DTI consistently outperformed state-of-the-art baseline models on multiple datasets and evaluation metrics.
  • Ablation studies confirmed the positive contribution of each proposed component to prediction accuracy.
  • The framework demonstrated enhanced generalization capability in DTI prediction.

Conclusions:

  • MFDR-DTI offers a robust and effective approach for predicting drug-target interactions.
  • The proposed feature decoupling and fusion mechanism significantly improves prediction performance.
  • The adaptive optimization strategy enhances training stability and efficiency in DTI prediction models.